Artwork

Content provided by CommonSpirit Health Physician Enterprise. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by CommonSpirit Health Physician Enterprise or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

5-Minute Check In: Tumor-Infiltrating Lymphocyte Therapy in Advanced Melanoma

7:28
 
Share
 

Manage episode 393563284 series 3291352
Content provided by CommonSpirit Health Physician Enterprise. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by CommonSpirit Health Physician Enterprise or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Guest: Dr. Christopher Huerter, Professor and Division Chief Dermatology at Creighton University School of Medicine
Breakthrough treatments: Checkpoint inhibitors like Ipilimumab have changed the way we treat melanoma. Now, a new cutting-edge adoptive cell therapy with tumor-infiltrating lymphocytes (TIL) has shown promise in metastatic melanoma treatment trials. A new phase III trial compares TIL to Ipilimumab immunotherapy as first- or second-line treatment in patients with advanced melanoma with remarkable results.
Article: https://www.nejm.org/doi/full/10.1056/NEJMoa2210233

  continue reading

101 episodes

Artwork
iconShare
 
Manage episode 393563284 series 3291352
Content provided by CommonSpirit Health Physician Enterprise. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by CommonSpirit Health Physician Enterprise or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Guest: Dr. Christopher Huerter, Professor and Division Chief Dermatology at Creighton University School of Medicine
Breakthrough treatments: Checkpoint inhibitors like Ipilimumab have changed the way we treat melanoma. Now, a new cutting-edge adoptive cell therapy with tumor-infiltrating lymphocytes (TIL) has shown promise in metastatic melanoma treatment trials. A new phase III trial compares TIL to Ipilimumab immunotherapy as first- or second-line treatment in patients with advanced melanoma with remarkable results.
Article: https://www.nejm.org/doi/full/10.1056/NEJMoa2210233

  continue reading

101 episodes

Alle episoder

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide